New hope for kids with hemophilia: altuviiio trial aims to tame inhibitors
NCT ID NCT07158606
First seen Jun 26, 2026 · Last updated Jul 28, 2026 · Updated 2 times
Summary
This phase 4 trial tests whether Altuviiio (efanesoctacog alpha) can help children with severe hemophilia A and high-titer inhibitors achieve immune tolerance. Participants also receive Hemlibra (emicizumab) to prevent bleeding. The study involves 15 children under 18 and will track success over up to 52 weeks of treatment, followed by tapering and monitoring.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- efanesoctacog alpha (Altuviiio) and emicizumab (Hemlibra)
- What this could lead to
- If successful, this could help children with hemophilia A and inhibitors achieve immune tolerance, reducing the need for frequent treatments and improving bleed control.
- What could go wrong
- This is a small, early-phase trial with only 15 participants, so results may not apply to everyone. The treatment requires ongoing medication, and success is not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A WITH INHIBITOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Versiti Wisconsin
Milwaukee, Wisconsin, 53226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.